Celularity Inc. terminated the employment of Rick Gonzalez as its Chief Commercial Officer, effective immediately on August 5, 2026. Mr. Gonzalez ceased serving in this role upon termination. Celularity Inc. operates in the biotechnology industry, focusing on cellular therapies and regenerative medicine.

Celularity Inc. received notice from Nasdaq on July 23, 2026, that its Class A common stock no longer complies with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market. The company has an 180-day compliance period until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to comply may result in delisting, though an additional grace period is possible if other listing standards are met. Celularity Inc. operates in the biotechnology industry, focusing on cellular therapies.